Cegedim S.A. (0DYQ)
London Exchange · UK · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 10.48 |
|---|---|
| 52-week range | 8.60 – 14.80 |
| Return, 1 month / 3 months | −3.9% / +3.6% |
| Return, 1 year / 3 years | −6.8% / −39.4% |
| Trend | Below its 200-day average |
| RSI (14) | 45 |
| Volatility (1 year) | 45.5% |
| Worst drawdown (1 year) | -41.9% |
| Average daily value traded | 0.00M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Cegedim is a French technology and services group based near Paris that focuses on the healthcare industry and on business software. It supplies doctors, pharmacists and other healthcare professionals with practice management software, electronic medical records and related services, and it provides healthcare data and marketing support to life-sciences companies. Its business services division offers payroll, human resources and customer relationship management software to companies in several sectors.
On this site Cegedim S.A. appears as a stock on the London Exchange (UK), code 0DYQ, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in one calendar year. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Cegedim S.A. (0DYQ) trades on the London Exchange in UK. It last closed at EUR 10.48 on 23 October 2026.
Its price-based Market X-Ray is 28 out of 100 (a weak price profile), ranking 3,148 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 6.8% and over the last three months it rose 3.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 27 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -11.8% | ||
| From 52-week high | -29.2% | ||
| Momentum | 43 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | 3.6% | ||
| 6-month return | -15.1% | ||
| 12-month return, skipping the last month | -3.1% | ||
| Stability (higher is calmer) | 31 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 45.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -41.9% | ||
| Liquidity | 2 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.00M EUR | ||
| Zero-volume days | 61.7% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 1 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +0.2% |
|---|---|
| 1 month | −3.9% |
| 3 months | +3.6% |
| 6 months | −15.1% |
| 1 year | −6.8% |
| 3 years | −39.4% |
| 5 years | −57.3% |
Signals
| 50-day / 200-day average | 10.96 / 11.88 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.18 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 29 Jun 2022 | EUR 0.5000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.